Biotech is a topic tracked in our intelligence system with 5 linked articles.
Colossal Biosciences is reportedly seeking new capital at a $20–$30 billion valuation, backed by prior $60 million government investments and multiple spinouts with notable funding/valuations, signaling potential upside but substantial execution and regulatory risks.
Reed Jobs' Yosemite has grown to a 17-person team amid a patent-cliff window and AI-driven strategy.
An opinion piece arguing about AI’s potential to cure diseases, anchored by a personal AML story and Basecamp Research, but hampered by garbled text and a lack of actionable data or regulatory detail.
TechCrunch tallies at least 80 VC-backed unicorns minted in 2025, dominated by AI startups with valuations mostly between $1B and $9B+ and a sprinkling of non‑AI players (satellites, fintech, biotech), based on Crunchbase and PitchBook.
BillionToOne goes public as YC’s fourth biotech IPO, boasting that 1 in 11 US babies are tested with its fetal DNA test, with rapid development from YC and a track record of FDA-cleared Covid testing and a 2023 cancer/liquid biopsy product, underscoring regulatory and execution advantages despite promotional framing.
AI industry leaders sign an open letter urging US Congress to require DNA/RNA sellers to screen orders, signaling a push for tighter biosecurity regulation that could impact biotech suppliers and AI developers.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.